公开(公告)号：US10023862B2

公开(公告)日：2018-07-17

申请号：US14371131

申请日：2013-01-08

申请人： Dieter Huesken ,  Brian Bettencourt ,  David Bumcrot ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Schlabach, Jr. ,  Frank P. Stegmeier ,  Markus Warmuth ,  Jan Weiler ,  NOVARTIS AG

发明人： Brian Richard Bettencourt ,  David Anton Bumcrot ,  Dieter Huesken ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Ray Schlabach, Jr. ,  Frank Peter Stegmeier ,  Markus Warmuth ,  Jan Weiler

IPC分类号： A61P35/00 ,  A61P17/02 ,  C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

公开(公告)号：US20150291954A1

公开(公告)日：2015-10-15

申请号：US14371131

申请日：2013-01-08

申请人： NOVARTIS AG

发明人： Brian Richard Bettencourt ,  David Anton Bumcrot ,  Dieter Huesken ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Ray Schlabach, JR. ,  Frank Peter Stegmeier ,  Markus Warmuth ,  Jan Weiler

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/713 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

摘要翻译： 本公开涉及可用于治疗β-联蛋白相关疾病如结肠腺瘤性息肉病，结肠直肠癌，基底细胞癌，乳腺癌，肾癌，Wilms肿瘤，成神经管细胞瘤，卵巢癌，肾上腺皮质肿瘤， 胃癌，肝癌，黑素瘤，胰腺癌，前列腺癌，肾癌，异位牙齿和口腔乳头，皮肤癌，皮质细胞瘤，间变性甲状腺癌和子宫癌肉瘤，少痣，骨质疏松症，衰老，退行性疾病，褥疮，慢性伤口和 损伤的伤口愈合以及类似和相关疾病，使用治疗有效量的RNAi剂到β-联蛋白。

公开(公告)号：US20130210771A1

公开(公告)日：2013-08-15

申请号：US13765713

申请日：2013-02-13

申请人： Novartis AG

发明人： Christine Dierks ,  Markus Warmuth

IPC分类号： A61K31/675 ,  A61K31/506 ,  A61K31/352 ,  A61K31/505 ,  A61K31/438 ,  A61K31/519 ,  A61K31/496

CPC分类号： A61K31/675 ,  A61K31/352 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/66 ,  A61K45/06 ,  A61K2300/00

摘要： This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.

摘要翻译： 本发明提供了刺猬蛋白信号传导途径的拮抗剂与BCR-ABL抑制剂的组合。 本发明的组合可用于治疗已知与蛋白酪氨酸激酶（例如Src，BCR-ABL和c-kit）相关的癌症。